(NASDAQ: COGT) Cogent Biosciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 117.27%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 22.74%.
Cogent Biosciences's revenue in 2025 is $0.On average, 13 Wall Street analysts forecast COGT's revenue for 2026 to be $6,677,032,081, with the lowest COGT revenue forecast at $0, and the highest COGT revenue forecast at $23,725,624,793. On average, 12 Wall Street analysts forecast COGT's revenue for 2027 to be $37,642,930,502, with the lowest COGT revenue forecast at $16,324,892,815, and the highest COGT revenue forecast at $69,740,295,200.
In 2028, COGT is forecast to generate $98,191,396,990 in revenue, with the lowest revenue forecast at $51,053,375,769 and the highest revenue forecast at $126,144,180,929.